Nouvelles perspectives et orientations futures dans le domaine des maladies infectieuses et de la santé cardiovasculaire

Café du cœur au CES 2025

2:30 PM – 3:30 PM – SESSION 2

Nouvelles perspectives et orientations futures dans le domaine des maladies infectieuses et de la santé cardiovasculaire

Nouvelles perspectives et orientations futures dans le domaine des maladies infectieuses et de la santé cardiovasculaire

Points forts de la session

In this WHF Heart Café conversation, Dorairaj Prabhakaran moderates a panel with Karen SliwaKavita Singh, and Sven Schellberg on the bidirectional links between infectious diseases (COVID-19, influenza, HIV) and cardiovascular disease (CVD). The discussion covers evidence on post-infection cardiovascular risk, the burden of long COVID, and pragmatic models for integrated, resilient health systems—including nurse-led teleconsultations, primary-care strengthening, and data interoperability in low- and middle-income settings.

Principaux enseignements

Infections can precipitate CVD events

Prior influenza and COVID-19 are associated with higher short-term risk of myocardial infarction and other events; people with CVD/risk factors faced ~3× higher COVID-19 mortality.

Long COVID is a cardiovascular issue

In a multi-country WHF cohort, 56% reported ≥1 symptom at 1 month (fatigue, dyspnea, chest pain, palpitations, anxiety); ~25% persisted at 9–12 months, with notable new diagnoses (e.g., pulmonary embolism, CKD, hypertension).

Endothelium & thrombosis

Omicron-era disease shows endothelial dysfunction and a pro-thrombotic milieu, helping explain late thrombotic events and some sudden deaths outside hospital.

Act early, at first contact

The “window of opportunity” in viral illness is short—equip nurses, CHWs, and GPs with protocols and decision support for timely assessment and treatment.

Integration beats silos

Intentionally embed BP/glucose checks and CVD risk management into infectious-disease pathways; use nurse-led telehealth and task-sharing to maintain chronic care during surges.

Systems levers

Prioritize interoperable datamedicine supply chains (e.g., insulin), patient navigation, and protection of vulnerable groups to sustain UHC goals.

Capacity & preparedness

Multi-country research networks build skills and evidence; keep COVID-19 learnings alive to prepare for the next pandemic.

Qui doit regarder ?

Cardiologists, GPs, nurses, public-health teams, policymakers, patient advocates, and digital-health leaders working on long COVIDthrombosis/endotheliumhypertension/diabetes programs, and integrated infectious-disease–CVD care in diverse health systems.

Maladies infectieuses et maladies cardiovasculaires - FAQ

COVID-19 augmente-t-il le risque cardiovasculaire après la guérison ?
Yes. Follow-up shows persistent symptoms and elevated events (e.g., thromboembolism). Likely drivers include endothelial injury and hypercoagulability.
Quelles sont les personnes les plus exposées au risque de complications ?
Older adults and people with hypertension, diabetes, obesity, or existing CVD—but clinicians should screen broadly; risk is not confined to the “usual suspects.”
Quelle intégration fonctionne dans la pratique ?
Embed BP/glucose monitoring in infectious-disease pathways, scale nurse-led teleconsultations, task-share at primary care, and ensure interoperable data across programs.
Que doivent faire les équipes de première ligne en cas d'afflux ?
Use simple, early protocols at first contact; triage for thrombotic risk; maintain access to essential meds via robust supply chains; and provide clear patient navigation.
Comment les spécialistes peuvent-ils aider au quotidien ?
Include vaccination and early-treatment guidance in clinic letters; flag infection control as a cardiovascular risk modifier to prompt timely GP/community action.